Sofinnova Crossover I SLP Reduces Stake in Abivax S.A. by Over $122 Million
Summary
Sofinnova Crossover I SLP, a major institutional investor, sold approximately $122.3 million worth of Abivax S.A. ADSs, reducing its beneficial ownership to 7.7% of voting rights.
Key Events
-
Significant Share Sales
Sofinnova Crossover I SLP sold a total of 1,000,000 ADSs across multiple transactions on January 12 and 13, 2026, for an aggregate value of approximately $122.3 million.
-
Reduced Ownership Stake
Following these sales, Sofinnova Crossover I SLP's beneficial ownership in Abivax S.A. now represents 7.7% of the outstanding voting rights.
-
Institutional Investor Divestment
The substantial reduction in stake by a major institutional investor like Sofinnova Crossover I SLP is a notable event for the company.
Analysis
Sofinnova Crossover I SLP, a significant institutional investor, has substantially reduced its position in Abivax S.A. by selling approximately $122.3 million worth of American Depositary Shares (ADSs). This divestment represents a notable reduction in their beneficial ownership, which now stands at 7.7% of the company's voting rights. While institutional investors often rebalance portfolios, a sale of this magnitude by a major shareholder can signal a shift in their investment thesis or a need for liquidity, potentially creating downward pressure on the stock.
At the time of this filing, ABVX was trading at $124.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $4.77 to $148.83. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.